Reuters logo
BRIEF-FDA grants orphan drug designation to ALXN1210
January 6, 2017 / 11:53 AM / 9 months ago

BRIEF-FDA grants orphan drug designation to ALXN1210

Jan 6 (Reuters) - Alexion Pharmaceuticals Inc :

* FDA grants orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh)

* FDA grants orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh)

* Alexion Pharmaceuticals - enrolling patients in phase 3 trials of ALXN1210 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below